{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} SGLT2 Inhibitors: What Role Do They Play in Heart Failure with Reduced Ejection Fraction?

Activity Steps

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Describe the stages and classifications of heart failure (HF) and guidelines for referrals.
  2. Summarize the pharmacodynamics and evidence-based guidelines regarding the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors for patients with HF.
  3. Explain the risks, benefits, and additional implications of SGLT2 inhibitors.

Learning Outcomes

By completing this activity and taking the posttest, participants will achieve a minimum score of 70%.
Price: $21.95

Credits:

  • ANCC 2.0 CH / 1.5 APH
  • DC - BON 2.0 CH
  • FL - BON 2.0 CH
  • GA - BON 2.0 CH

Lippincott Professional Development is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, Georgia Board of Nursing, New Mexico Board of Nursing, South Carolina Board of Nursing, and West Virginia Board of Examiners for Registered Professional Nurses, #50-1223.

Awarded Advanced Pharmacology Hours







Test Code: NP0721B
Published: Jul 2021
Expires: 6/7/2024
Required Passing Score: 8/10 (80%)
Authors: Christy McDonald Lenahan, DNP, FNP-BC, ENP-C, CNE; Deedra Harrington, DNP, MSN, ACNP-BC; Frances Stueben, DNP, RN, CHSE